[HTML][HTML] Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis
A Sabet, F Khalaf, T Haslerud, A Al-Zreiqat… - American journal of …, 2013 - ncbi.nlm.nih.gov
Bone metastases of gastroenteropancreatic neuroendocrine tumors (GEP NET) can be
associated with pain and a poor prognosis. Peptide receptor radionuclide therapy (PRRT) …
associated with pain and a poor prognosis. Peptide receptor radionuclide therapy (PRRT) …
Gastroenteropancreatic neuroendocrine tumors in children and young adults
G Khanna, SM O'Dorisio, Y Menda, P Kirby, S Kao… - Pediatric …, 2008 - Springer
We review the imaging findings of pediatric gastroenteropancreatic neuroendocrine tumors
(GEP-NETs) using contemporary anatomic and molecular imaging techniques. A low index …
(GEP-NETs) using contemporary anatomic and molecular imaging techniques. A low index …
Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?
A Sabet, F Khalaf, CJ Yong-Hing… - Nuklearmedizin …, 2014 - thieme-connect.com
Aim: Highly advanced metastatic bone disease with extensive osseous infiltration of
neuroendocrine tumours (NET) may preclude patients from treatment with peptide receptor …
neuroendocrine tumours (NET) may preclude patients from treatment with peptide receptor …
Correlation between standardized uptake value of 68Ga-DOTA-NOC positron emission tomography/computed tomography and pathological classification of …
The aim of our study was to correlate tumor uptake of 68 Ga-DOTA-NOC positron emission
tomography/computed tomography (PET/CT) with the pathological grade of neuroendocrine …
tomography/computed tomography (PET/CT) with the pathological grade of neuroendocrine …
[PDF][PDF] Лучевая и радионуклидная визуализация в диагностике АКТГ-продуцирующих нейроэндокринных опухолей
В ОпуХОЛЕ - Медицинская радиология и радиационная …, 2022 - researchgate.net
АКТГ-эктопированный синдром, обусловленный избыточной продукцией
адренокортикотропного гормона (АКТГ) нейроэндокринной опухолью (НЭО), является …
адренокортикотропного гормона (АКТГ) нейроэндокринной опухолью (НЭО), является …
Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors
S Ezziddin, A Sabet, T Logvinski… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Reported experience with systemic 131I-metaiodobenzylguanidine (131I-MIBG) therapy of
neuroendocrine tumors comprises different dosing schemes. The aim of this study was to …
neuroendocrine tumors comprises different dosing schemes. The aim of this study was to …
[HTML][HTML] Neuroendocrine tumors: a registry of 1000 patients
RN Younes - Revista da Associação Médica Brasileira, 2008 - SciELO Brasil
Neuroendocrine tumors (NET) can originate diffusely in most organs, with varying clinical
presentations. The relative rarity of these tumors, previously referred to as carcinoids …
presentations. The relative rarity of these tumors, previously referred to as carcinoids …
[HTML][HTML] Nuclear medicine imaging of neuroendocrine tumours
A Al-Nahhas - Clinical medicine, 2012 - ncbi.nlm.nih.gov
Neuroendocrine tumours (NETs) are a clinically diverse group of tumours which commonly
affect the gastroenteropancreatic tract and lungs. They are rare, with an incidence of 2 …
affect the gastroenteropancreatic tract and lungs. They are rare, with an incidence of 2 …
Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
DL Bushnell, MT Madsen, T O'cdorisio, Y Menda… - EJNMMI research, 2014 - Springer
Background Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment
for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient …
for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient …
[HTML][HTML] Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy
JAN Ahmad, BB Schroeder, SM Ruhoy… - Clinical nuclear …, 2022 - journals.lww.com
Background Peptide receptor radioligand therapy (PRRT) was Food and Drug
Administration approved in 2018 for the treatment of unresectable somatostatin receptor …
Administration approved in 2018 for the treatment of unresectable somatostatin receptor …